Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.
Source: medscape.com
📰 Norman Collisson News
Norman Collisson News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Norman Collisson. Real-time updates on events, politics, business and more.
Peter C Taylor, PhD: Nipocalimab Shows Promise in Rheumatoid Arthritis Treatment
Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.
Peterc Taylor Norman Collisson University Of Oxford Musculoskeletal Sciences Disease Activity Rheumatoid Arthritis
Source: hcplive.com
Peter C Taylor, PhD: Complexities of Treatment and Unmet Needs in Rheumatoid Arthritis
Peter C Taylor, PhD, discusses the current treatment landscape in rheumatoid arthritis and the unmet needs of this patient population.
Source: hcplive.com
Janssen's antibody drug shows phase 2 potential in rheumatoid arthritis
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn). The antibody drug nipocalimab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has shown early promise for treating rheumatoid arthritis (RA) in a phase 2a trial.
Peterc Taylor Norman Collisson University Of Oxford Momenta Pharmaceuticals American College Of Rheumatology Disease Activity Score
Source: biopharma-reporter.com
New survey promotes patient involvement in defining achievable treatment goals in Rheumatoid Arthritis
New survey promotes patient involvement in defining achievable treatment goals in Rheumatoid ArthritisResearch funded by Galapagos and presented at EULAR virtual congress, suggests a third of patients are unaware of treatment goals set by their doctorsLondon, United Kingdom; 02 June 2021; 14:30 BST; Galapagos today...
Source: pharmiweb.com